Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
biote Corp(BTMD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BTMD
11/11/2026: BTMD (1-star) is currently NOT-A-BUY. Pass it for now.
biote Corp is a provider of hormone optimization and wellness services, primarily known for its bioidentical hormone pellet therapy and physician education platform. Its main strength lies in a vertically integrated business model that creates consistent demand for its high-margin consumable products. The company’s primary growth opportunity is the continued expansion of its practitioner network and the integration of digital health tools. However, investors must consider risks including regulatory scrutiny over compounding, dependence on discretionary spending, and intense competition from large pharmaceutical firms. The stock may best suit growth-oriented investors, while those seeking dividends or low-volatility assets may find it less suitable given its current business stage.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Investors focusing on the expansion of the hormone optimization market may find potential here, but the stock requires patience given its growth-stage profile. |
| Momentum investor | Weak fit | Momentum is often conditional on positive breakout trends, which have been inconsistent for the stock. |
| Value investor | Weak fit | Valuation and profitability metrics currently present a challenge for traditional value-based investment approaches. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses on reinvesting cash into business growth. |
| Low-risk investor | Weak fit | The company's volatility and regulatory exposure make it less suitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock has experienced significant price swings, impacting short-term holder portfolios. |
| Valuation risk | Medium / high | Investors may face risks if future earnings growth does not justify the current market valuation. |
| Competition risk (pharmaceutical hormone therapies) | Medium | Large pharma players could introduce or promote competing products that impact biote's market share. |
| Business quality | Medium | The company is in a scaling phase, and operational consistency remains a focus for long-term quality. |
| Dividend income | Low / none | No dividend income is available to offset stock price declines. |
| Execution risk | Medium / high | The company must successfully scale its practitioner network and product supply chain to meet growth targets. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -74.27% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/11/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Sector & Industry Intelligence
Sector snapshot as of 2026-11-10
Sector
Healthcare
- Signal
- Constructive
- Sentiment
- Strong Bullish
- Market state
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 60.0%
- Active BUY / eligible
- 69 / 115
- 22-session BUY-count change
- +29
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Medical Care Facilities
- BUY participation
- 88.9%
- Active BUY / eligible
- 8 / 9
- 22-session BUY-count change
- +5
The sector signal does not change this stock’s BUY, SELL, or PASS advisory.
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 34.84M USD | Price to earnings Ratio - | 1Y Target Price 2.22 |
Price to earnings Ratio - | 1Y Target Price 2.22 | ||
Volume (30-day avg) 120.1K shares | Beta 1.74 | 52 Weeks Range 0.99 - 2.90 | Updated Date 11/11/2026 |
52 Weeks Range 0.99 - 2.90 | Updated Date 11/11/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.07 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Hormone Optimization Platform | Sale of hormone pellets and training fees from certified practitioners. | Revenue is generated primarily when doctors and clinics purchase the proprietary pellet supplies for their patients. |
| Nutraceuticals | Direct and wholesale sales of medical-grade supplements. | This segment provides an additional revenue stream by offering health supplements that complement the primary hormone therapy. |
| Practice Management Software | Subscription and licensing fees for software services. | Software fees provide a recurring revenue component to the business model. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate -0.05 | Actual 0.01 |
Profitability
Profit Margin -1.08% | Operating Margin (TTM) 5.74% |
Management Effectiveness
Return on Assets (TTM) 5.65% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 4.44 | Enterprise Value 149.30M | Price to Sales(TTM) 0.19 |
Enterprise Value 149.30M | Price to Sales(TTM) 0.19 | ||
Enterprise Value to Revenue 0.81 | Enterprise Value to EBITDA 6.36 | Shares Outstanding 27.04M | Shares Floating 15.58M |
Shares Outstanding 27.04M | Shares Floating 15.58M | ||
Percent Insiders 19.85 | Percent Institutions 61.44 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.